共 91 条
[1]
Markman M(1996)Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report Gynecol Oncol 62 4-6
[2]
Iseminger KA(2008)Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum Gynecol Oncol 110 56-9
[3]
Hatch KD(2011)Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer Clin Cancer Res 17 1591-602
[4]
Creasman WT(2013)PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity Anticancer Res 33 2997-3004
[5]
Barnes W(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35
[6]
Dubeshter B(2007)Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study Oncol Rep 18 1051-9
[7]
Ramirez PT(2007)Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clin Cancer Res 13 3617-22
[8]
Schmeler KM(2005)Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein Int J Gynecol Pathol 24 363-8
[9]
Milam MR(2000)Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein Oncogene 19 258-64
[10]
Slomovitz BM(2007)Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors Cancer Cell 12 479-91